- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 08.08. | Elevidys sales weaken; Neumora gets into obesity | ||
| 07.08. | Strand raises another $153M to make 'programmable' mRNA drugs | ||
| 07.08. | FDA to start new 'precheck' program to boost US drug production | ||
| 07.08. | Lilly shares fall as obesity pill misses expectations in key trial | ||
| 07.08. | FDA lifts pause on Valneva's chikungunya shot, but adds new limits | ||
| 07.08. | Arvinas, Pfizer reworking partnership on 'Protac' cancer drug | ||
| 07.08. | Iovance cuts staff amid slow sales start for 'TIL' cell therapy | ||
| 06.08. | HHS abandons mRNA vaccine research | ||
| 06.08. | Novo pushes back against obesity drug compounders as competition intensifies | ||
| 06.08. | Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share | ||
| 05.08. | Pharma prepared to work with Trump on DTC drug sales: Pfizer CEO | ||
| 05.08. | Trump threatens up to 250% tariffs on pharma imports | ||
| 05.08. | David Altshuler, geneticist who helped transform Vertex, to retire next year | ||
| 05.08. | Vertex plan to build on pain drug breakthrough hits hurdles | ||
| 04.08. | Gates Foundation pledges $2.5B toward women's health research | ||
| 04.08. | Drugmakers score policy win in fight against 340B | ||
| 04.08. | A brain biotech slumps even with 'best case' seizure data | ||
| 04.08. | Xoma strikes deals to buy struggling biotechs HilleVax, Lava | ||
| 04.08. | The race to scale to 1,000 liters and beyond in gene therapy manufacturing | ||
| 01.08. | Regeneron cancer bispecific rejected again; Allogene discloses trial death | ||
| 01.08. | Trump redoubles threats in attempt to strongarm drugmakers on prices | ||
| 01.08. | Experts ousted from CDC panel warn of damage to US vaccine policy | ||
| 31.07. | In rumored AbbVie deal, Wall Street sees momentum for psychedelics M&A | ||
| 31.07. | Alnylam reaches new highs on strong sales of closely watched rare disease drug | ||
| 31.07. | Venture firm Frazier closes $1.3B fund for early-stage biotech investing |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .